2023 Q2 Form 10-Q Financial Statement

#000168316823003389 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $10.75M $9.475M $5.592M
YoY Change 196.58% 69.43% 252.08%
Cost Of Revenue $8.755M $6.613M $1.774M
YoY Change 134.91% 272.83% 107.49%
Gross Profit $1.998M $2.862M $3.819M
YoY Change -2076.54% -25.05% 420.56%
Gross Profit Margin 18.58% 30.21% 68.28%
Selling, General & Admin $10.85M $6.501M $6.293M
YoY Change 174.36% 3.3% 115.69%
% of Gross Profit 542.91% 227.16% 164.81%
Research & Development $120.0K $0.00 $0.00
YoY Change -81.69% -100.0%
% of Gross Profit 6.0% 0.0% 0.0%
Depreciation & Amortization $177.4K $94.33K $62.65K
YoY Change 6.78% 50.57% 849.24%
% of Gross Profit 8.88% 3.3% 1.64%
Operating Expenses $11.15M $6.501M $6.458M
YoY Change 134.21% 0.67% 112.2%
Operating Profit -$9.149M -$3.639M -$2.640M
YoY Change 88.23% 37.87% 14.27%
Interest Expense -$249.3K $314.3K -$349.5K
YoY Change -62.28% -189.94% 118.43%
% of Operating Profit
Other Income/Expense, Net $902.2K -$406.6K -$3.970K
YoY Change 166.96% 10141.26% -963.04%
Pretax Income -$8.930M -$4.046M -$2.993M
YoY Change 65.31% 35.17% 21.2%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.236M -$4.026M -$3.423M
YoY Change 63.93% 17.6% 38.89%
Net Earnings / Revenue -76.59% -42.49% -61.21%
Basic Earnings Per Share -$0.05 -$0.05
Diluted Earnings Per Share -$0.09 -$0.05 -$48.74K
COMMON SHARES
Basic Shares Outstanding 88.70M shares 85.66M shares 70.24M shares
Diluted Shares Outstanding 85.73M shares 70.24M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $812.8K $1.289M $547.3K
YoY Change -8.86% 135.51% 106.36%
Cash & Equivalents $812.8K $1.289M $547.3K
Short-Term Investments
Other Short-Term Assets $1.343M $337.8K $161.6K
YoY Change 212.39% 109.01% -29.93%
Inventory $2.079M $2.321M $1.157M
Prepaid Expenses
Receivables $4.453M $8.218M $7.724M
Other Receivables $376.6K $534.8K $171.3K
Total Short-Term Assets $9.817M $12.83M $9.761M
YoY Change 2.65% 31.43% 311.48%
LONG-TERM ASSETS
Property, Plant & Equipment $1.476M $1.404M $2.139M
YoY Change 37.13% -34.38% 64.12%
Goodwill $3.803M $4.253M
YoY Change -10.59%
Intangibles $3.858M $3.920M
YoY Change 9.45%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $15.35M $15.90M $3.752M
YoY Change 19.39% 323.84% 35.76%
TOTAL ASSETS
Total Short-Term Assets $9.817M $12.83M $9.761M
Total Long-Term Assets $15.35M $15.90M $3.752M
Total Assets $25.17M $28.73M $13.51M
YoY Change 12.25% 112.62% 163.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.179M $4.598M $1.033M
YoY Change 122.09% 344.89% 161.94%
Accrued Expenses $1.084M $1.717M $3.903M
YoY Change -39.76% -56.0% -66.11%
Deferred Revenue $1.337M $1.973M
YoY Change 85.49%
Short-Term Debt $251.6K $16.73M $6.735M
YoY Change -97.66% 148.34% -30.72%
Long-Term Debt Due $439.6K $1.035M
YoY Change -34.3%
Total Short-Term Liabilities $10.02M $28.94M $13.57M
YoY Change -50.93% 113.22% -39.19%
LONG-TERM LIABILITIES
Long-Term Debt $2.709M $13.73M $10.02M
YoY Change -73.28% 37.0% 3240.93%
Other Long-Term Liabilities $8.188M $8.767M $836.2K
YoY Change 20.05% 948.43% 15.58%
Total Long-Term Liabilities $10.90M $22.49M $10.86M
YoY Change -35.75% 107.21% 960.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.02M $28.94M $13.57M
Total Long-Term Liabilities $10.90M $22.49M $10.86M
Total Liabilities $20.92M $51.44M $25.66M
YoY Change -44.04% 100.47% 9.78%
SHAREHOLDERS EQUITY
Retained Earnings -$141.7M -$133.5M
YoY Change 16.71%
Common Stock $443.5K $431.2K
YoY Change 22.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.109M -$23.54M -$12.14M
YoY Change
Total Liabilities & Shareholders Equity $25.17M $28.73M $13.51M
YoY Change 12.25% 112.62% 163.12%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$8.236M -$4.026M -$3.423M
YoY Change 63.93% 17.6% 38.89%
Depreciation, Depletion And Amortization $177.4K $94.33K $62.65K
YoY Change 6.78% 50.57% 849.24%
Cash From Operating Activities $5.462M -$5.163M -$2.837M
YoY Change -296.23% 81.97% 70.69%
INVESTING ACTIVITIES
Capital Expenditures $205.4K -$32.87K -$309.9K
YoY Change -187.55% -89.39% 747.54%
Acquisitions
YoY Change
Other Investing Activities $20.36K $9.110K
YoY Change -93.39%
Cash From Investing Activities -$185.1K $41.98K -$309.9K
YoY Change -351.64% -113.55% -1023.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -5.723M 4.873M 3.519M
YoY Change -287.5% 38.5% 104.56%
NET CHANGE
Cash From Operating Activities 5.462M -5.163M -2.837M
Cash From Investing Activities -185.1K 41.98K -309.9K
Cash From Financing Activities -5.723M 4.873M 3.519M
Net Change In Cash -446.5K -247.9K 371.5K
YoY Change -230.38% -166.73% 306.17%
FREE CASH FLOW
Cash From Operating Activities $5.462M -$5.163M -$2.837M
Capital Expenditures $205.4K -$32.87K -$309.9K
Free Cash Flow $5.256M -$5.130M -$2.528M
YoY Change -306.23% 102.98% 55.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000725394
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
usd
CY2021Q4 DFCO Issuance Of Preferred Stock
IssuanceOfPreferredStock
usd
CY2021Q4 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
usd
CY2021Q4 DFCO Reversal Of Shares Previously Issued To Directors
ReversalOfSharesPreviouslyIssuedToDirectors
usd
CY2022Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
usd
CY2023Q1 DFCO Common Stock Issued For Conversion Of Convertibles Notes Accrued Interest And Premium
CommonStockIssuedForConversionOfConvertiblesNotesAccruedInterestAndPremium
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-12641
dei Entity Registrant Name
EntityRegistrantName
DALRADA FINANCIAL CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
38-3713274
dei Entity Address Address Line1
EntityAddressAddressLine1
600 La Terraza Blvd.
dei Entity Address City Or Town
EntityAddressCityOrTown
Escondido
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92025
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
283-1253
dei Security12b Title
Security12bTitle
Common Stock, $0.005 par value per share
dei Trading Symbol
TradingSymbol
DFCO
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
88699139 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1288916 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
772062 usd
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8218196 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6406555 usd
CY2023Q1 DFCO Accounts Receivable Net Related Parties Current
AccountsReceivableNetRelatedPartiesCurrent
127951 usd
CY2022Q2 DFCO Accounts Receivable Net Related Parties Current
AccountsReceivableNetRelatedPartiesCurrent
41603 usd
CY2023Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
534761 usd
CY2022Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
288655 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
2321316 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
1624621 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
337828 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
430070 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
12828968 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
9563566 usd
CY2023Q1 us-gaap Long Term Investments And Receivables Net
LongTermInvestmentsAndReceivablesNet
41716 usd
CY2022Q2 us-gaap Long Term Investments And Receivables Net
LongTermInvestmentsAndReceivablesNet
42395 usd
CY2023Q1 DFCO Longterm Receivables Related Parties
LongtermReceivablesRelatedParties
1182893 usd
CY2022Q2 DFCO Longterm Receivables Related Parties
LongtermReceivablesRelatedParties
1209103 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1403890 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1076412 usd
CY2023Q1 us-gaap Goodwill
Goodwill
4253424 usd
CY2022Q2 us-gaap Goodwill
Goodwill
4253424 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3920496 usd
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3524888 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2713785 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1665436 usd
CY2023Q1 DFCO Right Of Use Asset Net Related Party
RightOfUseAssetNetRelatedParty
2385014 usd
CY2022Q2 DFCO Right Of Use Asset Net Related Party
RightOfUseAssetNetRelatedParty
1087256 usd
CY2023Q1 us-gaap Assets
Assets
28730186 usd
CY2022Q2 us-gaap Assets
Assets
22422480 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4597505 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2331919 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1717484 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1799404 usd
CY2023Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
0 usd
CY2022Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
2055736 usd
CY2023Q1 DFCO Accounts Payable And Accrued Liabilities Related Parties Current
AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent
1792753 usd
CY2022Q2 DFCO Accounts Payable And Accrued Liabilities Related Parties Current
AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent
1270133 usd
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1972516 usd
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
720923 usd
CY2023Q1 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
1035189 usd
CY2022Q2 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
669028 usd
CY2023Q1 DFCO Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
16726676 usd
CY2022Q2 DFCO Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
9269377 usd
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 usd
CY2022Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1495528 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
587527 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
435647 usd
CY2023Q1 DFCO Right Of Use Liability Related Party Current
RightOfUseLiabilityRelatedPartyCurrent
511772 usd
CY2022Q2 DFCO Right Of Use Liability Related Party Current
RightOfUseLiabilityRelatedPartyCurrent
369050 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
28941422 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
20416745 usd
CY2023Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
73205 usd
CY2022Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
120534 usd
CY2023Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
479001 usd
CY2022Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
479001 usd
CY2023Q1 DFCO Notes Payable Related Parties Noncurrent1
NotesPayableRelatedPartiesNoncurrent1
13174894 usd
CY2022Q2 DFCO Notes Payable Related Parties Noncurrent1
NotesPayableRelatedPartiesNoncurrent1
9538685 usd
CY2023Q1 DFCO Contingent Consideration
ContingentConsideration
4767333 usd
CY2022Q2 DFCO Contingent Consideration
ContingentConsideration
4870800 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2126258 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1231691 usd
CY2023Q1 DFCO Right Of Use Liability Related Party Non Current
RightOfUseLiabilityRelatedPartyNonCurrent
1873242 usd
CY2022Q2 DFCO Right Of Use Liability Related Party Non Current
RightOfUseLiabilityRelatedPartyNonCurrent
718206 usd
CY2023Q1 us-gaap Liabilities
Liabilities
51435355 usd
CY2022Q2 us-gaap Liabilities
Liabilities
37375662 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.005
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.005
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86240807 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86240807 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72174620 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72174620 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
431187 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
360855 usd
CY2023Q1 DFCO Common Stock To Be Issued
CommonStockToBeIssued
317925 usd
CY2022Q2 DFCO Common Stock To Be Issued
CommonStockToBeIssued
1066925 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
109222356 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
104627032 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-133492861 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121436490 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-21177 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-50673 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-23542420 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-15432201 usd
CY2023Q1 us-gaap Minority Interest
MinorityInterest
837251 usd
CY2022Q2 us-gaap Minority Interest
MinorityInterest
479019 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-22705169 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-14953182 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28730186 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22422480 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9290805 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5572826 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
18066932 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15530319 usd
CY2023Q1 DFCO Revenues Related Party
RevenuesRelatedParty
183888 usd
CY2022Q1 DFCO Revenues Related Party
RevenuesRelatedParty
19324 usd
DFCO Revenues Related Party
RevenuesRelatedParty
918648 usd
DFCO Revenues Related Party
RevenuesRelatedParty
111448 usd
CY2023Q1 us-gaap Revenues
Revenues
9474693 usd
CY2022Q1 us-gaap Revenues
Revenues
5592150 usd
us-gaap Revenues
Revenues
18985580 usd
us-gaap Revenues
Revenues
15641767 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6612680 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1773630 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11924140 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5034308 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
2862013 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
3818520 usd
us-gaap Gross Profit
GrossProfit
7061440 usd
us-gaap Gross Profit
GrossProfit
10607459 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
815454 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
362532 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2184692 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2145626 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6501233 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6458163 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18438927 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16000902 usd
CY2023Q1 DFCO Research And Development Expenses
ResearchAndDevelopmentExpenses
0 usd
CY2022Q1 DFCO Research And Development Expenses
ResearchAndDevelopmentExpenses
0 usd
DFCO Research And Development Expenses
ResearchAndDevelopmentExpenses
0 usd
DFCO Research And Development Expenses
ResearchAndDevelopmentExpenses
1596 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
6501233 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
6458163 usd
us-gaap Operating Expenses
OperatingExpenses
18438927 usd
us-gaap Operating Expenses
OperatingExpenses
16002498 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3639220 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2639643 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11377487 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5395039 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
314319 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
338677 usd
us-gaap Interest Expense
InterestExpense
2207049 usd
us-gaap Interest Expense
InterestExpense
597551 usd
CY2023Q1 us-gaap Interest Income Operating
InterestIncomeOperating
18830 usd
CY2022Q1 us-gaap Interest Income Operating
InterestIncomeOperating
4232 usd
us-gaap Interest Income Operating
InterestIncomeOperating
60725 usd
us-gaap Interest Income Operating
InterestIncomeOperating
5280 usd
CY2023Q1 us-gaap Other Income
OtherIncome
-72933 usd
CY2022Q1 us-gaap Other Income
OtherIncome
-3974 usd
us-gaap Other Income
OtherIncome
-179555 usd
us-gaap Other Income
OtherIncome
9270 usd
CY2023Q1 DFCO Gain On Expiration Of Accrued Tax Liability
GainOnExpirationOfAccruedTaxLiability
0 usd
CY2022Q1 DFCO Gain On Expiration Of Accrued Tax Liability
GainOnExpirationOfAccruedTaxLiability
0 usd
DFCO Gain On Expiration Of Accrued Tax Liability
GainOnExpirationOfAccruedTaxLiability
2090978 usd
DFCO Gain On Expiration Of Accrued Tax Liability
GainOnExpirationOfAccruedTaxLiability
0 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-38156 usd
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-15018 usd
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-85751 usd
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-59351 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-406578 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-353437 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-320652 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-642352 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4045798 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2993080 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11698139 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6037391 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-137 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4990 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
29496 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
34679 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4045935 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2998070 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11668643 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6002712 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-20234 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
430147 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
358232 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
3036854 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4025564 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3423227 usd
us-gaap Net Income Loss
NetIncomeLoss
-12056371 usd
us-gaap Net Income Loss
NetIncomeLoss
-9074245 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85728770 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70235384 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82356784 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72718261 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85728770 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70235384 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82356784 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72718261 shares
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-13407388 usd
CY2021Q3 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
6532206 usd
CY2021Q3 DFCO Joint Venture
JointVenture
169745 usd
CY2021Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
14826 usd
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
677507 usd
CY2021Q3 DFCO Profit Loss1
ProfitLoss1
-976673 usd
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
39344 usd
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-6980085 usd
CY2021Q4 DFCO Joint Venture
JointVenture
-1874244 usd
CY2021Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1105587 usd
CY2021Q4 DFCO Profit Loss1
ProfitLoss1
-2067638 usd
CY2021Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
325 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-9816053 usd
CY2022Q1 DFCO Common Stock Issued In Connection With Convertible Note
CommonStockIssuedInConnectionWithConvertibleNote
1542695 usd
CY2022Q1 DFCO Joint Venture
JointVenture
-7900 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
362532 usd
CY2022Q1 DFCO Profit Loss1
ProfitLoss1
-2993080 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4990 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-10916796 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-14953182 usd
CY2022Q3 DFCO Common Stock Issued For Conversion Of Convertibles Notes Accrued Interest And Premium
CommonStockIssuedForConversionOfConvertiblesNotesAccruedInterestAndPremium
1111397 usd
CY2022Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
172350 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
467517 usd
CY2022Q3 DFCO Profit Loss1
ProfitLoss1
-3170176 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
63762 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-16308332 usd
CY2022Q4 DFCO Common Stock Issued For Conversion Of Convertibles Notes Accrued Interest And Premium
CommonStockIssuedForConversionOfConvertiblesNotesAccruedInterestAndPremium
336091 usd
CY2022Q4 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
75459 usd
CY2022Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
901721 usd
CY2022Q4 DFCO Profit Loss1
ProfitLoss1
-4482165 usd
CY2022Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-34129 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-19511355 usd
CY2023Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
36667 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
815454 usd
CY2023Q1 DFCO Profit Loss1
ProfitLoss1
-4045798 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-137 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-22705169 usd
us-gaap Profit Loss
ProfitLoss
-11698139 usd
us-gaap Profit Loss
ProfitLoss
-6037391 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
530177 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
156897 usd
DFCO Share Based Compensation1
ShareBasedCompensation1
2184692 usd
DFCO Share Based Compensation1
ShareBasedCompensation1
2145626 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
146475 usd
DFCO Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
181009 usd
DFCO Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
0 usd
DFCO Bad Debt Expense
BadDebtExpense
640484 usd
DFCO Bad Debt Expense
BadDebtExpense
0 usd
DFCO Gain On Expiration Of Accrued Tax Liability
GainOnExpirationOfAccruedTaxLiability
2090978 usd
DFCO Gain On Expiration Of Accrued Tax Liability
GainOnExpirationOfAccruedTaxLiability
-0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2787677 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7388104 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
218817 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
103932 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
696695 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
314573 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-128542 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-123392 usd
us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
-26889 usd
us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
-0 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2241421 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
123063 usd
DFCO Increase Decrease In Longterm Payables
IncreaseDecreaseInLongtermPayables
-47329 usd
DFCO Increase Decrease In Longterm Payables
IncreaseDecreaseInLongtermPayables
0 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
522620 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
1967786 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-217742 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1100808 usd
us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
35242 usd
us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
72558 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1191593 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
441075 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10074709 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7566320 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
511515 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
441521 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
446923 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
206068 usd
DFCO Acquisition Of Business Net Of Cash
AcquisitionOfBusinessNetOfCash
80087 usd
DFCO Acquisition Of Business Net Of Cash
AcquisitionOfBusinessNetOfCash
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-878351 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-647589 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
11845764 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
7602059 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2932857 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
752256 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
-0 usd
us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
-0 usd
us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
1882144 usd
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
346910 usd
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-21717 usd
DFCO Repurchase Of Common Shares From Subsidiary
RepurchaseOfCommonSharesFromSubsidiary
-0 usd
DFCO Repurchase Of Common Shares From Subsidiary
RepurchaseOfCommonSharesFromSubsidiary
14826 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11440418 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8616229 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
487358 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
402320 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29496 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34679 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
772062 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
110285 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1288916 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
547284 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
DFCO Conversion Of Related Party Notes And Interest Into Preferred Stock
ConversionOfRelatedPartyNotesAndInterestIntoPreferredStock
0 usd
DFCO Conversion Of Related Party Notes And Interest Into Preferred Stock
ConversionOfRelatedPartyNotesAndInterestIntoPreferredStock
6532206 usd
DFCO Contribution Of Property And Equipment Into Joint Venture
ContributionOfPropertyAndEquipmentIntoJointVenture
0 usd
DFCO Contribution Of Property And Equipment Into Joint Venture
ContributionOfPropertyAndEquipmentIntoJointVenture
111185 usd
DFCO Issuance Of Shares To Joint Venture Partner
IssuanceOfSharesToJointVenturePartner
0 usd
DFCO Issuance Of Shares To Joint Venture Partner
IssuanceOfSharesToJointVenturePartner
58560 usd
DFCO Conversion Of Accounts Payablerelated Parties To Note Payablerelated Parties
ConversionOfAccountsPayablerelatedPartiesToNotePayablerelatedParties
0 usd
DFCO Conversion Of Accounts Payablerelated Parties To Note Payablerelated Parties
ConversionOfAccountsPayablerelatedPartiesToNotePayablerelatedParties
181744 usd
DFCO Common Stock And Warrants Issued In Connection With Convertible Note
CommonStockAndWarrantsIssuedInConnectionWithConvertibleNote
0 usd
DFCO Common Stock And Warrants Issued In Connection With Convertible Note
CommonStockAndWarrantsIssuedInConnectionWithConvertibleNote
1542695 usd
DFCO Conversion Of Convertible Note Payable Accrued Interest And Premium Into Common Stock
ConversionOfConvertibleNotePayableAccruedInterestAndPremiumIntoCommonStock
2327489 usd
DFCO Conversion Of Convertible Note Payable Accrued Interest And Premium Into Common Stock
ConversionOfConvertibleNotePayableAccruedInterestAndPremiumIntoCommonStock
0 usd
DFCO Increase In Right Of Use Asset And Liability
IncreaseInRightOfUseAssetAndLiability
1447488 usd
DFCO Increase In Right Of Use Asset And Liability
IncreaseInRightOfUseAssetAndLiability
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_80B_eus-gaap--NatureOfOperations_zEIxHcAQ2Efb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_826_zcpcAZfwPTj7">Organization and Nature of Operations</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada Financial Corporation, (“Dalrada”), was incorporated in September 1982 under the laws of the State of California. It was reincorporated in May 1983 under the laws of the State of Delaware and reincorporated again on May 5, 2020, under the laws of the state of Wyoming. Dalrada Financial Corporation trades under the symbol, OTCQB: DFCO.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since Dalrada’s inception, the Company has grown its footprint to include the unique business divisions: <b>Genefic</b>, <b>Dalrada Energy Services</b>, <b>Dalrada Precision Manufacturing</b>, and <b>Dalrada Technologies</b>. Dalrada’s global solutions directly address climate change, gaps in the health care industry, and technology needs that facilitate a new era of human behavior and interaction and ensure a bright future for the world around us.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Genefic</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Genefic, formerly named Dalrada Health, delivers advanced health care solutions with dedicated products, services, and systems. From virus and disease screening capabilities to pharmaceutical goods and holistic wellness clinics, this specialized division is committed to developing key health products, lifesaving medications and building comprehensive systems to increase capability, strive to keep people healthy with the goals of improving their quality of life and increasing their longevity– on a global level.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Empower Genomics (“Empower”)</b>- Empower is Dalrada’s wholly owned diagnostic laboratory which processes molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus. Empower has built up and maintained the testing capacity to handle surges in COVID-19 testing demands. Empower also offers genetic testing capabilities including Pharmacogenomics, Nutraceutical, Nutrition/Diet DNA and Exercise/Fitness DNA tests.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Pala Diagnostics (“Pala”)</b>- Pala is a joint venture diagnostic laboratory which processes both molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Solas Corp. (“Solas”)</b>- Solas manages and oversees wellness clinics throughout Southern California including the Sòlas Rejuvenation + Wellness clinics (“Sòlas”). Through advanced medical techniques and modern technology, Sòlas delivers a clinical experience that helps men and woman live their best life, whether it’s through simple cosmetic procedures, pain-reducing practices, or anti-aging therapies. Through its three locations, Sòlas prides itself on its dedicated service-focused, health-first approach. Its wellness &amp; rejuvenation clinics deliver with a focus on regenerative therapies, IV and injection services, cosmetic enhancements amongst a myriad of additional health centric services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>International Health Group (“IHG”)</b>- IHG provides highly trained nursing and medical assistants for hospitals and home health facilities since 2006. IHG Medical Assistant programs include Certified Nursing Assistant (“CNA") and Home Health Aide (“HHA”) training and the fast-track 22-Day CNA Certification Program at its state-approved testing facility.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Pacific Stem Cells (“PSC”)</b>- PSC markets and sells traditional biologics and human cells, tissues, and cellular and tissue-based products (HCT/Ps).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Watson Rx Solutions (“Watson”)</b>- In June 2022, Dalrada Life Sciences acquired Watson, an Alabama-based pharmacy with more than 30 years of experience in the retail medical and pharmaceutical industries. Watson helps manage disease states through education and prescription management while offering generic as well as specialty medications. Watson maintains pharmacy licenses in all 50 States including Washington D.C.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>GlanHealth (“GlanHealth”)</b>- Dalrada Health Products launched GlanHealth in 2020 to distribute alcohol-free hand sanitizers, surface cleaners, laundry aides, antimicrobial solutions, electrostatic sprayers, face masks, gloves, kits, and delivery equipment such as dispensers, stands, and ease of use packaging for the end consumer. GlanHealth leverages an extensive supply chain of producers, resellers, distributors, vendors, and formulators for the development, sale, and marketing of its products and services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Dalrada Energy Services</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada Energy Services (‘DES’) employs next-generation technology that enhances clean energy efforts while reducing the world’s carbon footprint. Through innovative products and commercial services, DES facilitates energy transition for universities, businesses, government buildings, and more.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Dalrada Energy Services (“DES”)</b>- DES provides end-to-end comprehensive energy service solutions in a robust commercial capacity, DES helps organizations meet environmental, social, and governance (“ESG”) goals and standards while mitigating negative environmental impacts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Bothof Brothers Construction (“Bothof”)</b>- Bothof is a licensed general contractor which provides a wide range of development, construction and design capabilities and expertise throughout the United States. Through Bothof’s extensive experience in construction and contracting, the DES division is able to provide a myriad of additional services to its private and public works customers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Dalrada Precision Manufacturing</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada Precision Manufacturing creates total manufacturing solutions that start with the design and development of high-quality machine parts and components, and end with an efficient global supply chain. This specialized business division can meet today’s high demands and solves industry challenges. Dalrada Precision Manufacturing is confident that it redefines the critical quality of the world’s top components and responds with in-house research, design, engineering, and distribution through a highly reliable global supply chain and improved time-to-market capabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Dalrada Precision Parts (“Precision”)</b>- Precision extends the client its engineering and operations team by helping devise unique manufacturing solutions tailored to their products. Dalrada Precision can enter at any stage of the product lifecycle from concept and design to mass production and logistics.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Likido Ltd. (“Likido”)</b>- Likido is an international engineering company developing advanced solutions for the harvesting and recycling of energy. Using its novel, heat pump systems (patent pending), Likido is working to revolutionize the renewable energy sector with the provision of innovative modular process technologies to maximize the capture and reuse of thermal energy for integrated heating and cooling applications. With uses across industrial, commercial and residential sectors, Likido provides cost savings and the minimized carbon emissions across global supply chains. Likido's technologies enable the effective recovery and recycling of process energy, mitigating against climate change and expected enhancement of quality of life through the provision of low-carbon heating and cooling systems.   </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Ignite I.T. (“Ignite”)</b>- Ignite is a manufacturer and seller of eco-friendly deep cleaners, parts washers and degreasers that are specially formulated to lift hydrocarbon-based dirt and grease from virtually all surfaces with minimal effort. Ignite products are non-flammable, non-corrosive, non-toxic, butyl-free, water-based, and leave a light citrus scent. Ignite is developed for all surfaces suitable for water and meet or exceed the most stringent industry-testing specifications. Ignites products are effective and available solutions to the increased demand for protecting employees from hazardous chemicals currently used and highlighted in recent federal and state regulations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Deposition Technologies (“DepTec”)</b>- Dalrada Precision Manufacturing acquired DepTec in April 2022. DepTec designs, develops, manufactures, and services chemical vapor and physical vapor deposition systems for the microchip and semiconductor industries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">DepTec has built a multitude of precision OEM parts for PVD (Physical vapor deposition) and refurbished systems which allow clients the option of purchasing the same model of system they’ve been using for decades – but with upgrades and improved efficiencies. DepTec also has its own PVD and CVD (Chemical Vapor Deposition) systems, EVOS-PVD and EVOS -CVD, which deposits metals and non-metals for microchips used in almost every standard and specialized microdevices made today and in the future. These systems can produce a superior film layer utilized in rugged high-stress environment designs and expect to meet the increased US market demand driven by the CHIPS and Science Act of 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Dalrada Technology Limited (“DTL”)- </b>Dalrada Precision Manufacturing Inc. entered into an Ownership Purchase Agreement to purchase all of the membership interests in Dalrada Technology Limited on March 1, 2023. DTL is a holding company for all European based Dalrada Precision entities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Dalrada Technologies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada Technologies has worked with some of the world’s most recognizable companies, providing digital engineering for cutting-edge software systems and offering a host of robust digital services. This business division connects the world with integrated technology and innovative solutions, delivering advanced capabilities and error-free results. Dalrada Technologies creates digital products with expert computer information technology and software engineering services for a variety of technical industries and clients in both B2B and B2C environments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Prakat (“Prakat”)</b>- Prakat is an ISO 9001-certified company that provides end-to-end technology services across various industries, improving the value chain. The Company specializes in test engineering, accessibility engineering, product engineering, application modernization, billing and revenue management, CRM, and block chain. Prakat provides global customers with software and technology solutions specializing in Test Engineering, Accessibility Engineering, Product Engineering and Application Modernization.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">Liquidity and Going Concern</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These condensed consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of March 31, 2023, the Company has an accumulated deficit of $<span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20230331_zepQgQS1QoVk" title="Accumulated deficit">133,492,861</span>. The Company closed a convertible debenture funding on February 4, 2022 for a total principal amount of $<span id="xdx_90B_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20220203__20220204_zoGmVQEJvQpe" title="Principal amount">3,000,000</span>. The continuation of the Company as a going concern is dependent upon the continued financial support from related parties, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing and generating profitable operations from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p>
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-133492861 usd
CY2022Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3000000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_ztXTqo4MZSuk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_861_zmSt4XU5deKl">Use of Estimates</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of these condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the valuation of inventory, valuation of accrued payroll tax liabilities, valuation of acquired assets and liabilities, variables used in the computation of share-based compensation, and deferred income tax asset valuation allowances.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zyMIun2GNdEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_869_zfbYKI4HNaA9">Concentrations of Credit Risk</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When estimating its allowance for credit losses related to revenues from Covid Testing, the Company differentiates its receivables based on the following customer types: healthcare insurers, government payers, and cash payers. Additionally, the Company applies assumptions and judgments for assessing collectability and determining net revenues and accounts receivable from its customers. Historical collection factors we considered for assessing collectability and determining net revenues and accounts receivable from our customers include the period that the receivables have been outstanding, history of payment amounts, status of collections due, and applicable statutes of limitations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended March 31, 2023, healthcare insurers and government payers accounted for over <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--HealthcareInsurersAndGovernmentPayersMember_zgwOzd9AH411" title="Concentrations of credit risk">29</span>% of total revenues or $<span id="xdx_90B_eus-gaap--Revenues_pp0p0_c20220701__20230331__srt--ProductOrServiceAxis__custom--HealthcareInsurersMember_zcaBAQ3DB1Kb" title="Revenues">5,567,245</span>. The accounts receivable related to both healthcare insurers and government payers was $<span id="xdx_907_eus-gaap--AccountsReceivableNet_iI_pp0p0_c20230331__srt--ProductOrServiceAxis__custom--HealthcareInsurersAndGovernmentPayersMember_z8vGFbMR8hg5" title="Accounts Receivable, after Allowance for Credit Loss">3,863,560</span> as of March 31, 2023.</p>
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
223062 usd
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
119791 usd
CY2022Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
218308 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2023Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0 usd
CY2022Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9474693 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5592150 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18985580 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15641767 usd
CY2023Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
8218196 usd
CY2022Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
6406555 usd
CY2023Q1 DFCO Accounts Receivable Net Related Parties Current
AccountsReceivableNetRelatedPartiesCurrent
127951 usd
CY2022Q2 DFCO Accounts Receivable Net Related Parties Current
AccountsReceivableNetRelatedPartiesCurrent
41603 usd
CY2023Q1 us-gaap Long Term Investments And Receivables Net
LongTermInvestmentsAndReceivablesNet
41716 usd
CY2022Q2 us-gaap Long Term Investments And Receivables Net
LongTermInvestmentsAndReceivablesNet
42395 usd
CY2023Q1 DFCO Longterm Receivables Related Parties Current
LongtermReceivablesRelatedPartiesCurrent
1182893 usd
CY2022Q2 DFCO Longterm Receivables Related Parties Current
LongtermReceivablesRelatedPartiesCurrent
1209103 usd
CY2023Q1 us-gaap Deferred Revenue
DeferredRevenue
1972516 usd
CY2022Q2 us-gaap Deferred Revenue
DeferredRevenue
720923 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
362532 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6612680 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1773630 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11924140 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5034308 usd
us-gaap Advertising Expense
AdvertisingExpense
275846 usd
us-gaap Advertising Expense
AdvertisingExpense
366551 usd
CY2023Q1 us-gaap Advertising Expense
AdvertisingExpense
74846 usd
CY2022Q1 us-gaap Advertising Expense
AdvertisingExpense
138551 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
815454 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2184692 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2145626 usd
DFCO Change In Fair Value Of Contingent Consideration1
ChangeInFairValueOfContingentConsideration1
103467 usd
CY2023Q1 DFCO Contingent Consideration
ContingentConsideration
4767333 usd
CY2021Q3 DFCO Contribution Of Property And Equipment Into Joint Venture
ContributionOfPropertyAndEquipmentIntoJointVenture
111185 usd
CY2022Q4 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
30000 usd
CY2022Q4 DFCO Warrants Issued
WarrantsIssued
3000000 shares
CY2022Q4 DFCO Strike Price
StrikePrice
0.15
CY2022Q4 DFCO Cashless Warrants Vest
CashlessWarrantsVest
450000 usd
CY2022Q4 DFCO Cashless Warrants
CashlessWarrants
6000000 usd
CY2022Q4 DFCO Warrant Consideration
WarrantConsideration
3482550 usd
CY2022Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
70979 usd
CY2022Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
27289 usd
CY2022Q4 DFCO Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Right Of Use Asset Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssetNet
18618 usd
CY2022Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
17179 usd
CY2022Q4 DFCO Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Trade Name
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradeName
6776 usd
CY2022Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
24165 usd
CY2022Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
18807 usd
CY2022Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Deferred Revenue
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
60000 usd
CY2022Q4 DFCO Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Right Of Use Liability
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesRightOfUseLiability
18618 usd
CY2022Q4 DFCO Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Notes Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable
19251 usd
CY2022Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
0 usd
CY2023Q1 us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Rate
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationRate
1 pure
CY2023Q1 DFCO Warrants Issued
WarrantsIssued
1000000 shares
CY2023Q1 DFCO Strike Price
StrikePrice
0.10
CY2023Q1 DFCO Warrant Consideration
WarrantConsideration
68975 usd
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
9108 usd
CY2023Q1 DFCO Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deposits
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeposits
13536 usd
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
24666 usd
CY2023Q1 DFCO Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Furniture And Fixtures
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFurnitureAndFixtures
64533 usd
CY2023Q1 DFCO Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Trade Name
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradeName
206336 usd
CY2023Q1 DFCO Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Loan Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanPayable
249204 usd
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
68975 usd
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
1193509 usd
CY2022Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
399706 usd
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1127807 usd
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1224915 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
2321316 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
1624621 usd
CY2023Q1 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
1474850 usd
CY2022Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
740147 usd
CY2023Q1 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
303922 usd
CY2022Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
314642 usd
CY2023Q1 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
429027 usd
CY2022Q2 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
518017 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2207799 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1572806 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
803909 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
496394 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1403890 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1076412 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
265749 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
103566 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
94331 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9313 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3670665 usd
DFCO Finite Lived Intangible Assets Additions
FiniteLivedIntangibleAssetsAdditions
654554 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
4325219 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
145777 usd
DFCO Finite Lived Intangible Assets Accumulated Amortization Additions
FiniteLivedIntangibleAssetsAccumulatedAmortizationAdditions
258946 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
404723 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3920496 usd
CY2021Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
693385 usd
CY2022 DFCO Finite Lived Intangible Assets Additions
FiniteLivedIntangibleAssetsAdditions
2977280 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3670665 usd
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
28891 usd
CY2022 DFCO Finite Lived Intangible Assets Accumulated Amortization Additions
FiniteLivedIntangibleAssetsAccumulatedAmortizationAdditions
116886 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
145777 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3524888 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
264428 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
155570 usd
CY2023Q1 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
87334 usd
CY2022Q1 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
120131 usd
CY2023Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
0 usd
CY2022Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
2055736 usd
DFCO Accrued Interest Rate
AccruedInterestRate
Accrued interest is compounded daily at an estimated effective interest rate of 7.33%.
CY2023Q1 DFCO Notes Payable Related Parties
NotesPayableRelatedParties
29901570 usd
CY2023Q1 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
968011 usd
CY2022Q2 DFCO Notes Payable Related Parties
NotesPayableRelatedParties
18808062 usd
CY2022Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
362855 usd
CY2023Q1 DFCO Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
16726676 usd
CY2023Q1 DFCO Notes Payable Related Parties Noncurrent1
NotesPayableRelatedPartiesNoncurrent1
13174894 usd
CY2023Q1 DFCO Notes Payable Related Parties
NotesPayableRelatedParties
29901570 usd
CY2022Q2 DFCO Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
9269377 usd
CY2022Q2 DFCO Notes Payable Related Parties Noncurrent1
NotesPayableRelatedPartiesNoncurrent1
9538685 usd
CY2022Q2 DFCO Notes Payable Related Parties
NotesPayableRelatedParties
18808062 usd
us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
3320 usd
CY2023Q1 us-gaap Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
466460 usd
us-gaap Line Of Credit Facility Interest Rate Description
LineOfCreditFacilityInterestRateDescription
interest rate of Prime + 1%
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2021-05-05
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
600000 usd
DFCO Redemption Premium In Cash
RedemptionPremiumInCash
120000 usd
DFCO Debenture In Cash
DebentureInCash
600000 usd
CY2023Q1 DFCO Revenues Related Party
RevenuesRelatedParty
183888 usd
CY2022Q1 DFCO Revenues Related Party
RevenuesRelatedParty
19324 usd
DFCO Revenues Related Party
RevenuesRelatedParty
918648 usd
DFCO Revenues Related Party
RevenuesRelatedParty
111448 usd
us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
Each share of Series G Convertible Preferred share converts into 2,177 shares of common stock (equivalent to converting the related equity dollars into common shares at $0.30 per share).
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.45
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.59
CY2022Q1 DFCO Fair Value Of Options Granted
FairValueOfOptionsGranted
1338644 usd
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.45
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
250000 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.15
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1000000 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
11025004 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.45
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022 us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
0 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12025004 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
5200000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.27
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
17225004 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.40
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
12882260 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.43
us-gaap Share Based Compensation
ShareBasedCompensation
2184692 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2145626 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3521116 usd
CY2023Q1 us-gaap Revenues
Revenues
9474693 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3639220 usd
CY2022Q1 us-gaap Revenues
Revenues
5592150 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2639643 usd
us-gaap Revenues
Revenues
18985580 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11377487 usd
us-gaap Revenues
Revenues
15641767 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5395039 usd
us-gaap Revenues
Revenues
18985580 usd
us-gaap Revenues
Revenues
15641767 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
2321316 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
1624621 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1403890 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1076412 usd
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2405540 usd
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2405540 usd
CY2020Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.030 pure
CY2020Q2 DFCO Imputed Interest
ImputedInterest
192521 usd
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
140569 usd
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
140569 usd
CY2020Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.030 pure
CY2020Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.030 pure
CY2023Q1 us-gaap Notes Payable
NotesPayable
509731 usd

Files In Submission

Name View Source Status
dfco-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001683168-23-003389-index-headers.html Edgar Link pending
0001683168-23-003389-index.html Edgar Link pending
0001683168-23-003389.txt Edgar Link pending
0001683168-23-003389-xbrl.zip Edgar Link pending
dalrada_ex3101.htm Edgar Link pending
dalrada_ex3102.htm Edgar Link pending
dalrada_ex3201.htm Edgar Link pending
dalrada_ex3202.htm Edgar Link pending
dalrada_i10q-033123.htm Edgar Link pending
dfco-20230331.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
dfco-20230331_def.xml Edgar Link unprocessable
dfco-20230331_lab.xml Edgar Link unprocessable
dfco-20230331_pre.xml Edgar Link unprocessable
dalrada_i10q-033123_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending